SELLAS Life Sciences Group, Inc. ( SLS) - Key Metrics
SLS Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0 | -$0.05 | -$0.04 | -$0.04 |
| 2026Q1 | $0 | -$0.05 | -$0.05 | -$0.05 |
| 2025Q4 | $0 | -$0.05 | -$0.03 | -$0.03 |
| 2025Q3 | $0 | -$0.06 | -$0.07 | -$0.07 |
| 2025Q2 | $0 | -$0.07 | -$0.08 | -$0.08 |
SLS Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -73.80 |
| 2026Q1 | 0% | -21.71 |
| 2025Q4 | 0% | -18.85 |
| 2025Q3 | 0% | -6.43 |
| 2025Q2 | 0% | -8.17 |
SLS
Price: $12.78
52 week price:
Earnings Per Share: -0.22 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 183300
Ebitda: -4.4 millionMarket Capitalization: 2.5 billion